Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Insight

DelveInsight’s, “Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 10+ pipeline drugs in Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Understanding

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Overview

Neoantigen-based personalized cancer vaccines are individualized immunotherapies designed using tumor-specific mutations unique to each patient. Through genomic sequencing and bioinformatics analysis, neoantigens are identified and incorporated into vaccine platforms such as mRNA, peptide, DNA, or viral vectors to stimulate a targeted immune response against cancer cells while sparing normal tissues.

The mechanism of action of neoantigen-based personalized cancer vaccines involves identifying tumor-specific neoantigens from a patient's cancer mutations and incorporating them into a customized vaccine. After administration, antigen-presenting cells process and present these neoantigens, activating CD4+ helper and CD8+ cytotoxic T cells. The activated T cells then recognize and destroy tumor cells expressing the targeted neoantigens while sparing healthy tissues, potentially generating long-term immune memory against cancer recurrence. Because neoantigens are unique to cancer cells, they provide highly specific targets that minimize off-target effects. The antitumor immune response can be further enhanced when these vaccines are combined with immune checkpoint inhibitors.

The process begins with sequencing a patient's tumor and normal tissue to identify cancer-specific mutations. Selected neoantigens are then formulated into a personalized vaccine and administered to the patient. Antigen-presenting cells process these neoantigens and activate CD4+ and CD8+ T cells, which recognize and destroy tumor cells expressing the corresponding neoantigens, resulting in a highly specific antitumor immune response.

Personalized neoantigen vaccines offer high tumor specificity because neoantigens are absent from normal tissues, reducing the risk of off-target toxicity and autoimmune effects. They can induce durable T-cell responses, generate immunological memory, and may enhance the efficacy of immune checkpoint inhibitors. Advances in sequencing technologies and mRNA platforms have further accelerated their clinical development. Despite their promise, these vaccines face several challenges, including complex and time-consuming manufacturing, high costs, difficulties in accurately predicting immunogenic neoantigens, tumor heterogeneity, and immune escape mechanisms. In addition, vaccine production must be customized for each patient, creating logistical and scalability hurdles.

"Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline landscape is provided which includes the disease overview and Neoantigen-Based Personalized Cancer Therapeutic Vaccines treatment guidelines. The assessment part of the report embraces, in depth Neoantigen-Based Personalized Cancer Therapeutic Vaccines commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neoantigen-Based Personalized Cancer Therapeutic Vaccines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neoantigen-Based Personalized Cancer Therapeutic Vaccines R&D. The therapies under development are focused on novel approaches to treat/improve Neoantigen-Based Personalized Cancer Therapeutic Vaccines. 

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Emerging Drugs Analysis

This segment of the Neoantigen-Based Personalized Cancer Therapeutic Vaccines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Emerging Drugs

mRNA-415: Moderna, Inc./ Merck & Co., Inc.

mRNA-4157(V940) is an investigational personalized mRNA neoantigen cancer vaccine that encodes up to 34 patient-specific tumor neoantigens identified through genomic sequencing. It is designed to stimulate a targeted T-cell immune response against cancer cells based on the unique mutational profile of an individual's tumor. mRNA-4157 (V940), in combination with KEYTRUDA® (pembrolizumab), has received FDA Breakthrough Therapy Designation and EMA PRIME designation for the adjuvant treatment of patients with high-risk melanoma. Currently, the drug is in Phase III stage of its development for the treatment of Resected High-Risk (Stage IIB-IV) Melanoma.

TG4050: Transgene/NEC Bio B.V.

TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene's myvac® technology and powered by NEC's longstanding Artificial Intelligence (AI) and Machine Learning (ML) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences. TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Squamous Cell Carcinoma of Head and Neck.

VB10.NEO: Nykode Therapeutics

VB10.NEO is a proprietary individualized neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors. The vaccine is designed to be produced on-demand according to the neoantigen profile of an individual patient. Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues and are thus an attractive target for cancer immunotherapy as they may be recognized as foreign by the immune system. It has been shown to be generally well tolerated and with an ability to generate uniquely broad patient- and tumor-specific long-lasting immune responses. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Solid Tumors.

Further product details are provided in the report……..

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Drug Therapeutic Assessment

This segment of the report provides insights about the different Neoantigen-Based Personalized Cancer Therapeutic Vaccines drugs segregated based on following parameters that define the scope of the report, such as:

Major Neoantigen-Based Personalized Cancer Therapeutic Vaccines Players in Neoantigen-Based Personalized Cancer Therapeutic Vaccines

There are approx. 8+ key companies which are developing the therapies Neoantigen-Based Personalized Cancer Therapeutic Vaccines. The companies which have their Neoantigen-Based Personalized Cancer Therapeutic Vaccines drug candidates in the most advanced stage, i.e. Phase III include, Moderna, Inc./ Merck & Co., Inc. and others.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Clinical Trial Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 Neoantigen-Based Personalized Cancer Therapeutic Vaccines Drug Route of Administration

Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Clinical Trial Activities

The Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline report provides insights into different Neoantigen-Based Personalized Cancer Therapeutic Vaccines Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Neoantigen-Based Personalized Cancer Therapeutic Vaccines therapeutic drugs key players involved in developing key drugs. 

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Development Activities

The Neoantigen-Based Personalized Cancer Therapeutic Vaccines Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neoantigen-Based Personalized Cancer Therapeutic Vaccines drugs.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Report Insights

• Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Analysis
• Neoantigen-Based Personalized Cancer Therapeutic Vaccines Therapeutic Assessment
• Neoantigen-Based Personalized Cancer Therapeutic VaccinesUnmet Needs
• Impact of Neoantigen-Based Personalized Cancer Therapeutic Vaccines Drugs

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Report Assessment

• Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Product Profiles
• Neoantigen-Based Personalized Cancer Therapeutic Vaccines Therapeutic Assessment
• Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Assessment
• Neoantigen-Based Personalized Cancer Therapeutic Vaccines Inactive drugs assessment
• Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Unmet Needs

Key Questions Answered in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Neoantigen-Based Personalized Cancer Therapeutic Vaccines drugs?
• How many Neoantigen-Based Personalized Cancer Therapeutic Vaccines drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neoantigen-Based Personalized Cancer Therapeutic Vaccines?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neoantigen-Based Personalized Cancer Therapeutic Vaccines therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Neoantigen-Based Personalized Cancer Therapeutic Vaccines and their status?
• What are the key designations that have been granted to the emerging drugs?

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Key Players

• Moderna, Inc.
• Merck & Co., Inc.
• Transgene
• NEC Bio B.V.
• Nykode Therapeutics
  Evaxion A/S

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Key Products

• mRNA-415
• TG4050
• VB10.NEO
• EVX-01
• GRT-C901